Send to

Choose Destination
Vaccine. 2017 Jun 27;35(30):3764-3772. doi: 10.1016/j.vaccine.2017.05.043. Epub 2017 Jun 2.

Immunogenicity and safety of a new hexavalent vaccine (DTaP5-IPV-HB-Hib) administered in a mixed primary series schedule with a pentavalent vaccine (DTaP5-IPV-Hib).

Author information

Translational Pediatrics and Infectious Diseases, Department of Pediatrics, Hospital Clinico Universitario de Santiago de Compostela, c/ A Choupana s.n., 15706 Santiago de Compostela, Spain. Electronic address:
Sanofi Pasteur MSD, 162 Avenue Jean Jaurès, CS 50712, 69367 Lyon Cedex 07, France. Electronic address:
Sanofi Pasteur MSD, 162 Avenue Jean Jaurès, CS 50712, 69367 Lyon Cedex 07, France. Electronic address:
Sanofi Pasteur MSD, 162 Avenue Jean Jaurès, CS 50712, 69367 Lyon Cedex 07, France. Electronic address:
Manchester Medical Microbiology Partnership, Public Health England, PO Box 209, Clinical Sciences Building, Manchester Royal Infirmary, Manchester M13 9WZ, UK. Electronic address:


DTaP5-IPV-HB-Hib vaccine is a fully-liquid, combination hexavalent vaccine. This phase III, open-label, multicentre study conducted in Spain, evaluated the immune response to all DTaP5-IPV-HB-Hib antigens when the vaccine was used in a mixed hexa/penta/hexa primary series. Infants (who had received one dose of hepatitis B vaccine at birth) received a mixed schedule including DTaP5-IPV-HB-Hib (PRP-OMP conjugate) at 2 and 6months of age, DTaP5-IPV-Hib at 4months, meningococcal serogroup C conjugate (MCC) vaccine at 2 and 4months, and routine rotavirus and pneumococcal vaccination. One month post-dose 3 of the mixed schedule, response rates were considered acceptable if the lower bound of the two-sided 95% confidence interval around the post-vaccination response rate was >90% for hepatitis B and >80% for Haemophilus influenzae type b (Hib). Secondary immunogenicity objectives included description of the antibody response to all hexavalent antigens one month after completion of the mixed schedule, and to MCC antigen one month after the second MCC dose. The safety profile after each dose of study vaccine was described. Of 385 healthy infants enrolled, 384 completed the study. The primary objective was achieved for both hepatitis B and Hib; the lower bound of the 2-sided 95% CI of the response rates (97.2% and 99.0%, respectively) were greater than the pre-specified acceptability thresholds. One month post-dose 3 of the mixed schedule, all participants were seroprotected against diphtheria, tetanus and polio. The mixed schedule induced a robust immune response to all hexavalent antigens. The co-administration of the hexavalent vaccine in a mixed schedule with MCC vaccine did not reduce the immune response to vaccine antigens. Vaccines were well tolerated. In conclusion, the acceptability of response rates against Hib and hepatitis B were demonstrated one month post-dose 3 of the mixed schedule; robust immune responses against all other hexavalent antigens were observed. NCT01839188; EudraCT: 2012-004221-25.


DTaP5-IPV-HB-Hib; Mixed schedule; Primary series; Safety profile; Vaccine immune response

[Indexed for MEDLINE]

Publication types, MeSH terms, Substances, Secondary source IDs

Publication types

MeSH terms


Secondary source IDs

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center